Scemblix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(9 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(16 years from now)

Scemblix is owned by Novartis.

Scemblix contains Asciminib Hydrochloride.

Scemblix has a total of 2 drug patents out of which 0 drug patents have expired.

Scemblix was authorised for market use on 29 October, 2021.

Scemblix is available in tablet;oral dosage forms.

Scemblix can be used as treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml).

Drug patent challenges can be filed against Scemblix from 2025-10-29.

The generics of Scemblix are possible to be released after 14 May, 2040.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-10-29

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)


More Information on Dosage

SCEMBLIX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic